Qureight to showcase the use of AI-driven imaging in transforming respiratory disease research and drug development at ATS 2026 International Conference

During the show Qureight will be presenting four mini symposia and four posters, highlighting findings from multiple clinical studies and demonstrating how its enterprise-grade imaging and precision endpoints for clinical trials are enabling a new era of disease monitoring, outperforming current approaches.

The mini symposia and posters explore four key themes:

Idiopathic Pulmonary Fibrosis:

• Across large IPF datasets, baseline lung function shows minimal ability to predict future decline, and short-term change is unstable.
• Imaging tells a different story—early signal is driven by inflammatory change, while longer-term progression reflects fibrosis.
• Disease is not static, and single global endpoints fail to capture its dynamics.

Connective Tissue Disease:

• In connective tissue disease interstitial lung disease (ILD), the disconnect is even clearer. Baseline fibrosis does not predict progression.
• In systemic sclerosis, vascular volume—not fibrosis—tracks functional decline, while in myositis-related ILD, it is fibrotic progression, not burden, that matters.
• Across diseases, imaging biomarkers outperform diagnostic labels.

Working With Pharma:

• In clinical trials, quantitative CT provides something we’ve never really had: objective cohort definition.
• Trial populations can be placed directly within the context of real-world disease, exposing both alignment and hidden heterogeneity.

Pulmonary Hypertension:

• In pulmonary vascular disease, we show that standard CTPA contains a latent vascular biomarker.
• AI-derived blood volume measures outperform conventional metrics and even echocardiography for PH detection—unlocking entirely new endpoints from existing scans.

Confirmed activity at the conference includes:

Mini Symposium: Correlation Between Baseline FVC And Subsequent Longitudinal Change In Real-world IPF Datasets: Implications For FVC Change Prediction

• Date: 17 May, 15:39-15:51 EDT
• Location: W415 A (Level IV, OCCC West Concourse)

Mini Symposium: Associations Between Ground Glass Opacity, Fibrosis And Lung Function In Idiopathic Pulmonary Fibrosis

• Date: 17 May, 15:27-15:39 EDT
• Location: W415 A (Level IV, OCCC West Concourse)

Mini Symposium: Deep Learning-derived Fibrotic and Inflammatory Phenotypes Predict Lung Function Across Idiopathic and Connective-tissue-related Interstitial Lung Disease

• Date: 17 May, 15:03-15:15 EDT
• Location: W415 A (Level IV, OCCC West Concourse)

Mini Symposium: AI-Based Quantification of Pulmonary Blood Volumes From CT Pulmonary Angiography Helps Screen for Pulmonary Hypertension

• Date: 17 May, 10:15-10:27 EDT
• Location: W415 A (Level IV, OCCC West Concourse)

Poster: Structure-function Coupling and Quantitative Imaging Biomarkers in Polymyositis Dermatomyositis Associated Interstitial Lung Disease

• Date: 18 May, 09:15-11:15 EDT
• Location: Poster board 715, W314 (Level III, OCCC West Concourse)

Poster: Imaging-Physiology Dissociation and the Role of Pulmonary Vasculature in Systemic Sclerosis-Associated ILD

• Date: 19 May, 11:30-13:15 EDT
• Location: Poster board P1810, Area K, Halls WA2-WA3 (Level II, OCCC West Concourse)

Poster: Buloxibutid’s Efficacy in the Phase 2a Air IPF Trial: Comparative Analysis of Baseline Characteristics of Indian Versus World Cohorts

• Date: 19 May, 14:15-16:15 EDT
• Location: Poster board 522, West F3 (Level II, OCCC West Concourse)

Poster: Deep Learning-based HRCT Assessment of Baseline Disease Severity in the Deupirfenidone Elevate IPF Trial: Comparison With a Well-Characterised IPF Population

• Date: 18 May, 09:15-11:15 EDT
• Location: Poster board 708, W314 (Level III, OCCC West Concourse)